Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 11/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783157 | 1.00 | SCNN1A (0.35) | SCNN1AENPP2ATXN2GHSRALDH1A1 | |
| SCHEMBL782922 | 0.97 | SCNN1A (0.34) | SCNN1AENPP2ATXN2GHSRALDH1A1 | |
| SCHEMBL782920 | 0.97 | SCNN1A (0.34) | SCNN1AENPP2ATXN2GHSRALDH1A1 | |
| SCHEMBL2127750 | 0.92 | SCNN1A (0.38) | SCNN1AGHSRALDH1A1MEN1KMT2A | |
| SCHEMBL2127759 | 0.92 | SCNN1A (0.38) | SCNN1AGHSRALDH1A1MEN1KMT2A | |
| SCHEMBL781270 | 0.91 | USP2 (0.31) | ENPP2ATXN2ALDH1A1 | |
| SCHEMBL781272 | 0.91 | USP2 (0.31) | ENPP2ATXN2ALDH1A1 | |
| SCHEMBL1684644 | 0.90 | SCNN1A (0.40) | SCNN1AENPP2ATXN2GHSRALDH1A1 | |
| SCHEMBL781520 | 0.90 | SCNN1A (0.45) | SCNN1AENPP2ATXN2GHSRALDH1A1 | |
| SCHEMBL781518 | 0.90 | SCNN1A (0.45) | SCNN1AENPP2ATXN2GHSRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444120-B1 | Spirocyclic amiloride analogues as ENac blockers | NOVARTIS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
| WO-2009074575-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | SCNN1A 16/4885ENPP2 793/4885ATXN2 1191/4885 |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | SCNN1B, SCNN1A, SCNN1G | SCNN1A 2/4885ENPP2 723/4885ATXN2 832/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | SCNN1A 2/4885ENPP2 723/4885ATXN2 832/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | SCNN1A 6/4885ENPP2 2181/4885ATXN2 1781/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | SCNN1A 16/4885ENPP2 793/4885ATXN2 1191/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | SCNN1A 29/4885ENPP2 3702/4885ATXN2 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.